UNBELIEVABLE: 23 - Caught on Camera

Novo Nordisk cuts sales and profits guidance amid obesity drug competition

The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ever’.

Evening Standard · Nov 5, 2025

Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera

Pfizer and Novo Nordisk are in a heated battle to acquire obesity drug developer Metsera, driving legal and market tension.

International Business Times · Nov 5, 2025

Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported third-quarter 2025 sales of roughly $11.75 billion (74.98 billion Danish kroner), slightly below the consensus of $11.88 billion.

Benzinga · Nov 5, 2025

Child obesity crisis: London has worst record in weight surge for primary school youngsters, report reveals

More than a fifth of Year Six pupils in the capital are obese, according to new study

Evening Standard · Nov 4, 2025

Mapped: The areas where almost one in three children are obese

The figures were called ‘extremely concerning’ by the NHS national clinical director for children and young people

The Independent UK · Nov 4, 2025

Obesity levels among Reception and Year 6 children in England, by local area

The figures have been published as part of the Government’s National Child Measurement Programme.

Evening Standard · Nov 4, 2025

Pfizer Sues Rivals Metsera, Novo Nordisk Over Alleged Interference in Merger Talks

Pfizer sues Metsera and Novo Nordisk to block a rival bid in a high-stakes obesity drug merger.

International Business Times · Nov 1, 2025

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.

Benzinga · Oct 31, 2025

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

Benzinga · Oct 30, 2025

Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a bidding war over the drugmaker Metsera

The Independent UK · Oct 30, 2025